The addition of high-dose IV MTX and/or cytarabine was associated with lower incidence of CNS relapse compared with IT chemotherapy alone. However, these data are limited by their retrospective nature and warrant confirmation in prospective randomised studies.
No takes yet. Share an insight, caveat, or question.
Cheah et al. (2014) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: